Polio and routine immunisation Alan Brooks GAVI Alliance Board - - PowerPoint PPT Presentation

Alan Brooks

Polio and routine immunisation

GAVI Alliance Board meeting Geneva, Switzerland, 11-12 June 2013

GAVI Alliance Board meeting 11-12 June 2013

Background

1

GAVI Alliance Board meeting 11-12 June 2013

History of polio eradication

2

100 200 300 400 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

Polio cases (thousands)

World Health Assembly Resolution

India’s last case of wild virus Eliminated from Americas

Previous eradication targets

Last case

• f wild

type 2 virus Africa initiates Campaigns

GAVI Alliance Board meeting 11-12 June 2013

Polio Eradication and Endgame Strategic Plan (2013-2018)

3

2013 Last wild polio case Last OPV2 use Global Certification bOPV cessation 2014 2015 2016 2017 2018 2019

Begin phasing

• ut OPV

Stop OPV Last wild polio case Global certification

Objective 2: Routine immunisation, IPV, & OPV phasing out

Strengthen routine immunisation

Begin phasing in IPV Complete IPV IPV in routine immunisation Prepare to phase out OPV Phasing out OPV

• Oral polio vaccines (OPV) causing a growing percentage of cases
• Inactivated polio vaccine (IPV) in routine immunisation could
• Prevent polio cases caused by oral polio vaccine
• Help mitigate against risk of outbreaks

GAVI Alliance Board meeting 11-12 June 2013

GAVI’s complementary role to the Global Polio Eradication Initiative (GPEI) in the eradication effort

• Inactivated polio vaccine implementation
• Share lessons from over 130 routine programme new

vaccine introductions over 13 years

• Immunisation strategies & support to countries
• Advocacy and communications with consistent

messages

• Potential for resource mobilisation through

innovative financing instruments

• Ongoing investments through Business Plan

4

GAVI Alliance Board meeting 11-12 June 2013

IPV: GAVI Alliance’s comparative advantage supporting introduction into routine immunisation

• Proven approach, track record in implementation

and established lines of communication

• GAVI estimates 50-60 introductions (e.g.

pneumo) per year through 2015

• Country-driven policies and processes
• Existing investments through the business plan
• Opportunity to coordinate vaccine introductions

(and mitigate risk toGAVI programmes)

5

GAVI Alliance Board meeting 11-12 June 2013

Introduction timing (2014) 2015 2016-2020 2015-2024 52 countries in 2015 (GPEI official scenario) 90 245 490 10 priority countries in 2015; 42 in 2016 35 250 440

Costs

6

Estimated IPV costs (1 dose) (US$ Millions)

• Includes vaccine procurement, syringes,

safety boxes and freight

• Vaccine introduction grants: Additional

approximately US$40 million

• Does not include India

GAVI Alliance Board meeting 11-12 June 2013

Potential GAVI programme and policy implications

• Issues for GAVI, GPEI, WHO and others to work on

prior to November Board, include:

Analyses or new data

• Coordinated IPV plan, including demand forecast
• Contingency plan around Endgame timeline
• Coverage targets to achieve purpose

Policy or processes

• Coverage requirement (eligibility) to apply for IPV
• Application, review, approval, and monitoring
• Co-financing (and default)

7

GAVI Alliance Board meeting 11-12 June 2013

PPC Recommendation

• Request the Secretariat – recognising the urgency of timing in the

polio eradication effort and that considerations for Inactivated Polio Vaccine (IPV) are not consistent with the VIS criteria or timing – to prepare for procurement and implementation of GAVI support for the introduction of IPV in the routine immunisation programmes of GAVI countries as recommended by WHO as a contribution to polio eradication. These preparations and implementation shall take into account forthcoming recommendations from SAGE and be in consultation with Alliance

• partners. Approval will be subject to sufficient additional funding

being available and Board endorsement of moving this forward

• utside the timing of the VIS process and the Board will note that

there may need to be changes to GAVI policies which would need to be approved by the Board or the Executive Committee.

8

GAVI Alliance Board meeting 11-12 June 2013

Additional considerations for implementing the PPC recommendation

• Availability of additional funding
• Implementation:
• Based on country-driven decisions to introduce IPV,

that are part of national planning processes

• Carried out using GAVI’s structures, policies and

processes in so far as this is possible, recognizing that some exceptions may need to made

• Mitigating potential risk to achieving GAVI’s business plan

targets

9

GAVI Alliance Board meeting 11-12 June 2013

10